Rituximab, B-lymphocyte depletion, and preservation of beta-cell function

Pescovitz, Mark D.; Greenbaum, Carla J.; Krause-Steinrauf, Heidi; Becker, Dorothy J.; Gitelman, Stephen E.; Goland, Robin; Gottlieb, Peter A.; Marks, Jennifer B.; McGee, Paula F.; Moran, Antoinette M.; Raskin, Philip; Rodriguez, Henry; Schatz, Desmond A.; Wherrett, Diane; Wilson, Darrell M.; Lachin, John M.; Skyler, Jay S.

doi:10.1056/nejmoa0904452

Cited by 1,093Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function

Open access

Pescovitz, Mark D., Greenbaum, Carla J., Krause-Steinrauf, Heidi, Becker, Dorothy J., Gitelman, Stephen E., Goland, Robin, Gottlieb, Peter A., Marks, Jennifer B. +9 more·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0904452PMC PMC6410357

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The immunopathogenesis of type 1 diabetes mellitus is associated with T-lymphocyte autoimmunity. However, there is growing evidence that B lymphocytes play a role in many T-lymphocyte-mediated diseases. It is possible to achieve selective depletion of B lymphocytes with rituximab, an anti-CD20 monoclonal antibody. This phase 2 study evaluated the role of B-lymphocyte depletion in patients with type 1 diabetes. METHODS: We conducted a randomized, double-blind study in which 87 patients between 8 and 40 years of age who had newly diagnosed type 1 diabetes were assigned to receive infusions of rituximab or placebo on days 1, 8, 15, and 22 of the study. The primary outcome, assessed 1 year after the first infusion, was the geometric mean area under the curve (AUC) for the serum C-peptide level during the first 2 hours of a mixed-meal tolerance test. Secondary outcomes included safety and changes in the glycated hemoglobin level and insulin dose. RESULTS: At 1 year, the mean AUC for the level of C peptide was significantly higher in the rituximab group than in the placebo group. The rituximab group also had significantly lower levels of glycated hemoglobin and required less insulin. Between 3 months and 12 months, the rate of decline in C-peptide levels in the rituximab group was significantly less than that in the placebo group. CD19+ B lymphocytes were depleted in patients in the rituximab group, but levels increased to 69% of baseline values at 12 months. More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion. The reactions appeared to be minimal with subsequent infusions. There was no increase in infections or neutropenia with rituximab. CONCLUSIONS: A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0904452

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

After promising phase 1-2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.
“Disappointingly, after promising phase 1–2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.135–141”
From Type 1 diabetes (2014) · cites this paper as [136]
Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
The drug categories that preserve C-peptide include rituximab, teplizumab, otelixizumab, abatacept, and alefacept.
“These drugs include a monoclonal antibody against the B-cell CD20 receptor (rituximab),147 monoclonal antibodies against the T-cell CD3 receptor (teplizumab148,149 and otelixizumab150), cytotoxic T-lymphocyte protein 4 (CTLA4)-immunoglobulin-mediated co-stimulatory blockade with abatacept,151 and alefacept,152”
From Type 1 diabetes (2018) · cites this paper as [147]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · see citing works
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439 · see citing works
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996 · see citing works
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222 · see citing works
Self-citation
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099 · see citing works
Autoimmune Diseases
Davidson, A., & Diamond, B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450506 · Cited by 1,069 · see citing works
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R., Li, N. F., Agarwal, S. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,061 · see citing works
The Autoimmune Diseases
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 962 · see citing works
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab
Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F. M., Arend, L. J., Sloand, J. A., Rosenblatt, J. D., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20430 · Cited by 779 · see citing works
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 626 · see citing works
Self-citation
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536 · see citing works
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520 · see citing works
C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function
Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.1.250 · Cited by 491 · see citing works
Self-citation
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis
Cambridge, G., Leandro, M. J., Edwards, J., Ehrenstein, M. R., Salden, M., Bodman‐Smith, M. D., & WEBSTER, A. D. B. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11181 · Cited by 470 · see citing works
Risk Factors for Cyclosporine-Induced Nephropathy in Patients with Autoimmune Diseases
Feutren, G., & Mihatsch, M. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206183262502 · Cited by 408 · see citing works
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T., Varns, C., Shuey, S., Czuczman, M. S., Lynch, J. W., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008389119525 · Cited by 368 · see citing works
Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes
Greenbaum, C. J., Mandrup-Poulsen, T. R., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., & Kolb, H. (2008) · Diabetes Care · doi:10.2337/dc07-2451 · Cited by 285 · see citing works
Self-citation
B-Cells Are Required for the Initiation of Insulitis and Sialitis in Nonobese Diabetic Mice
Noorchashm, H., Noorchashm, N., Kern, J. H., Rostami, S. Y., Barker, C. F., & Naji, A. (1997) · Diabetes · doi:10.2337/diab.46.6.941 · Cited by 265 · see citing works
Rituximab treatment of idiopathic membranous nephropathy
Fervenza, F. C., Cosío, B. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E. J., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 264 · see citing works
Development of Type 1 Diabetes despite Severe Hereditary B-Cell Deficiency
Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W. A., Kolb, H., Noordzij, J. G., & Roep, B. O. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010465 · Cited by 253 · see citing works
I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice.
Noorchashm, H., Lieu, Y. K., Noorchashm, N., Rostami, S. Y., Greeley, S. A. W., Schlachterman, A., Song, H. K., Noto, L. E., Jevnikar, A. M., Barker, C. F., et al. (1999) · PubMed · Cited by 229 · see citing works
Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases
Ochs, H. D., Davis, S. D., & WEDGWOOD, R. J. P. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106756 · Cited by 223 · see citing works
Plasma Cell Development in Synovial Germinal Centers in Patients with Rheumatoid and Reactive Arthritis
Kim, H. J., Krenn, V., Steinhauser, G., & Berek, C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.3053 · Cited by 218 · see citing works
I-Ag7-Mediated Antigen Presentation by B Lymphocytes Is Critical in Overcoming a Checkpoint in T Cell Tolerance to Islet β Cells of Nonobese Diabetic Mice
Noorchashm, H., Lieu, Y. K., Noorchashm, N., Rostami, S. Y., Greeley, S. A. W., Schlachterman, A., Song, H. K., Noto, L. E., Jevnikar, A. M., Barker, C. F., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.743 · Cited by 211 · see citing works
Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study
Genovese, M. C., Kaine, J., Lowenstein, M. B., Giudice, J. D., Baldassare, A. R., Schechtman, J., Fudman, E. J., Kohen, M. D., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 208 · see citing works
Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations
Rivera, A., Chen, C.-C., Ron, N., Dougherty, J. P., & Ron, Y. (2001) · International Immunology · doi:10.1093/intimm/13.12.1583 · Cited by 204 · see citing works
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
Lapointe, R., Bellemare‐Pelletier, A., Housseau, F., Thibodeau, J., & Hwu, P. (2003) · PubMed · Cited by 189 · see citing works
Erratum
(2004) · Diabetes · doi:10.2337/diabetes.53.7.1934 · Cited by 120 · see citing works
Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments
Cattaneo, C. M., Spedini, P., Casari, S., Re, A., Tucci, A., Borlenghi, E., Ungari, M., Ruggeri, G. M., & Rossi, G. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500473113 · Cited by 116 · see citing works
B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice
Noorchashm, H., Noorchashm, N., Kern, J. H., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.6.941 · Cited by 102 · see citing works
Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174
Bearden, C. M., Agarwal, A., Book, B. K., Vieira, C. A., Sidner, R. A., Ochs, H. D., Young, M., & Pescovitz, M. D. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2003.00646.x · Cited by 93 · see citing works
Self-citation
Mixed Models: Theory and Applications (Wiley Series in Probability and Statistics)
Demidenko, E. (2004) · Wiley-Interscience eBooks · Cited by 76 · see citing works
Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses
Agarwal, A., Vieira, C. A., Book, B. K., Sidner, R. A., Fineberg, N. S., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00502.x · Cited by 60 · see citing works
Self-citation
The Role of B Lymphocytes as Key Antigen-Presenting Cells in the Development of T Cell-Mediated Autoimmune Type 1 Diabetes
SERREZE, D. V., & Silveira, P. A. (2002) · KARGER eBooks · doi:10.1159/000066863 · Cited by 55 · see citing works
The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation
Pescovitz, M. D. (2004) · Pediatric Transplantation · doi:10.1046/j.1397-3142.2003.00135.x · Cited by 41 · see citing works
Self-citation
The Role of T/B Lymphocyte Collaboration in the Regulation of Autoimmune and Alloimmune Responses
Noorchashm, H., Greeley, S. A. W., & Naji, A. (2003) · Immunologic Research · doi:10.1385/ir:27:2-3:443 · Cited by 21 · see citing works
Lessons Learned from Use of Cyclosporine for Insulin‐Dependent Diabetes Mellitus
Mahon, J. L., DUPRE, J., & STILLER, C. R. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17171.x · Cited by 20 · see citing works
Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results
Yilmaz, M. T., Devrim, A. S., Biyal, F., Satman, İ., Oral, E. A., Dınççağ, N., Karşıdağ, K., Özden, İ., Gürel, N., Sipahioğlu, F., et al. (1993) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(93)90108-h · Cited by 11 · see citing works
Progress in the Immunointervention of Type-1 Diabetes Mellitus
Schernthaner, G. (1995) · Hormone and Metabolic Research · doi:10.1055/s-2007-980023 · Cited by 7 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[24]Demidenko E Mixed models: theory and applications. Hoboken, NJ: John Wiley, 2004.

Sorted by citations

Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369 · see citing works
Type 1 diabetes
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,713 · see citing works
Type 1 diabetes
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561 · see citing works
Type 1 diabetes mellitus
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475 · see citing works
Self-citation
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381 · see citing works
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · see citing works
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022 · see citing works
Adverse effects of biologics: a network meta-analysis and Cochrane overview.
Singh, J. A., Wells, G., Christensen, R., Tanjong-Ghogomu, E., Maxwell, L. J., Macdonald, J., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 966 · see citing works
Effector and regulatory B cells: modulators of CD4+ T cell immunity
Lund, F. E., & Randall, T. D. (2010) · Nature reviews. Immunology · doi:10.1038/nri2729 · Cited by 638 · see citing works
Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments
Antar, S. A., Ashour, N. A., Sharaky, M. M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 749 · see citing works
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612 · see citing works
Self-citation
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · see citing works
Etiology of Type 1 Diabetes
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560 · see citing works
Treating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 544 · see citing works
Immune cell crosstalk in type 1 diabetes
Lehuen, A., Diana, J., Zaccone, P., & Cooke, A. (2010) · Nature reviews. Immunology · doi:10.1038/nri2787 · Cited by 478 · see citing works
Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial
Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., Boyle, K. D., Keyes-Elstein, L., Aggarwal, S., Phippard, D., et al. (2013) · Diabetes · doi:10.2337/db13-0345 · Cited by 410 · see citing works
Self-citation
Diabetes
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 387 · see citing works
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8980 · Cited by 377 · see citing works
Self-citation
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371 · see citing works
Self-citation
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
Moran, A., Bundy, B. N., BECKER, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Greenbaum, C. J., Herold, K. C., Marks, J. B., Raskin, P., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60023-9 · Cited by 356 · see citing works
Self-citation
Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342 · see citing works
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus
Ludvigsson, J., Krisky, D., Casas, R., Battelino, T., Castaño, L., Greening, J., Kordonouri, O., Otonkoski, T., Pozzilli, P., Robert, J.-J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107096 · Cited by 340 · see citing works
Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes
Leete, P., O’Connell, A., Krogvold, L., Dahl‐Jørgensen, K., Foulis, A. K., Richardson, S. J., & Morgan, N. G. (2016) · Diabetes · doi:10.2337/db15-1615 · Cited by 330 · see citing works
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
(PDWP), O. B. O. T. E. A. D. W. P. (. A. P. D. W. P., Snowden, J. A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., Denton, C. P., Hawkey, C. J., Labopin, M., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.185 · Cited by 327 · see citing works
Fall in C-Peptide During First 2 Years From Diagnosis
Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes · doi:10.2337/db11-1538 · Cited by 319 · see citing works
Self-citation
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
Long, S. A., Rieck, M., Sanda, S., Bollyky, J., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., et al. (2012) · Diabetes · doi:10.2337/db12-0049 · Cited by 315 · see citing works
Self-citation
The Pathogenesis and Natural History of Type 1 DiabetesPreprint
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 318 · see citing works
Altered B cell signalling in autoimmunity
Rawlings, D. J., Metzler, G., Wray-Dutra, M. N., & Jackson, S. W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.24 · Cited by 308 · see citing works
How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 311 · see citing works
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K., Tsalikian, E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81722 · Cited by 291 · see citing works
Self-citation
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Pescovitz, M. D., Greenbaum, C. J., Bundy, B. N., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., Moran, A., Raskin, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0626 · Cited by 290 · see citing works
Self-citation
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans
Menard, L. C., Saadoun, D., Isnardi, I., Ng, Y.-S., Meyers, G., Massad, C., Price, C. C., Abraham, C., Motaghedi, R., Buckner, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45790 · Cited by 289 · see citing works
Rituximab treatment of myasthenia gravis: A systematic review
Tandan, R., Hehir, M. K., Waheed, W., & Howard, D. B. (2017) · Muscle & Nerve · doi:10.1002/mus.25597 · Cited by 277 · see citing works
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273 · see citing works
Self-citation
Advances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Yu, Q., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 271 · see citing works
Genome-Wide Association Analysis of Autoantibody Positivity in Type 1 Diabetes Cases
Plagnol, V., Howson, J. M. M., Smyth, D. J., Walker, N. M., Hafler, J. P., Wallace, C., Stevens, H. E., Jackson, L. K., Simmonds, M. J., Bingley, P. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002216 · Cited by 262 · see citing works
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
Quattrin, T., Haller, M. J., Steck, A. K., Felner, E. I., Li, Y., Xia, Y., Leu, J. H., Zoka, R., Hedrick, J. A., Rigby, M. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006136 · Cited by 255 · see citing works
Stem cell therapies for treating diabetes: progress and remaining challenges
Sneddon, J. B., Tang, Q., Stock, P., Bluestone, J., Roy, S., Desai, T., & Hebrok, M. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.016 · Cited by 222 · see citing works
Verapamil and beta cell function in adults with recent-onset type 1 diabetes
Ovalle, F., Grimes, T., Xu, G., Patel, A. J., Grayson, T. B., Thielen, L. A., Li, P., & Shalev, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0089-4 · Cited by 249 · see citing works
Type 1 diabetes
Quattrin, T., Mastrandrea, L. D., & Walker, L. S. K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00223-4 · Cited by 261 · see citing works
Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes
Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes · doi:10.2337/db13-0236 · Cited by 247 · see citing works
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
Arif, S., Leete, P., Nguyen, V., Marks, K., Nor, N. M., Estorninho, M., Kronenberg‐Versteeg, D., Bingley, P. J., Todd, J. A., Guy, C., et al. (2014) · Diabetes · doi:10.2337/db14-0365 · Cited by 240 · see citing works
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T. R., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 236 · see citing works
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237 · see citing works
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Townsend, M. J., Monroe, J. G., & Chan, A. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00945.x · Cited by 233 · see citing works
Autoimmune polyglandular syndromes
Michels, A. W., & Gottlieb, P. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.40 · Cited by 233 · see citing works
Self-citation
How Does Type 1 Diabetes Develop?
Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Hebrok, M., Herold, K. C., Accili, D., Pietropaolo, M., Arvan, P. R., Von Herrath, M., Markel, D. S., et al. (2011) · Diabetes · doi:10.2337/db10-1797 · Cited by 232 · see citing works
Guidelines on the use of extracorporeal photopheresis
Knobler, R., Berlin, G., Calzavara‐Pinton, P., Greinix, H., Jaksch, P., Laroche, L., Ludvigsson, J., Quaglino, P., Reinisch, W., Scarisbrick, J. J., et al. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12311 · Cited by 219 · see citing works
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Huwiler, A., & Zangemeister‐Wittke, U. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.001 · Cited by 223 · see citing works
The immunology of type 1 diabetes
Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-023-00985-4 · Cited by 222 · see citing works
Immunotherapy: Building a bridge to a cure for type 1 diabetes
Bluestone, J. A., Buckner, J. H., & Herold, K. C. (2021) · Science · doi:10.1126/science.abh1654 · Cited by 215 · see citing works
Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214 · see citing works
Self-citation
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Rigby, M. R., DiMeglio, L. A., Rendell, M., Felner, E. I., Dostou, J. M., Gitelman, S. E., Patel, C. M., Griffin, K., Tsalikian, E., Gottlieb, P. A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70111-6 · Cited by 209 · see citing works
Self-citation
Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
Orban, T., Bundy, B. N., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0604 · Cited by 210 · see citing works
Self-citation
Environmental Triggers of Type 1 DiabetesPreprint
Knip, M., & Simell, O. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007690 · Cited by 206 · see citing works
B Cells in Autoimmune Diseases
Hampe, C. S. (2012) · Scientifica · doi:10.6064/2012/215308 · Cited by 201 · see citing works
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective
Kasi, P. M., Tawbi, H. A.-H., Oddis, C. V., & Kulkarni, H. S. (2012) · Critical Care · doi:10.1186/cc11304 · Cited by 194 · see citing works
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186 · see citing works
Connecting Type 1 and Type 2 Diabetes through Innate ImmunityPreprint
Odegaard, J. I., & Chawla, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007724 · Cited by 185 · see citing works
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes
Haller, M. J., Schatz, D., Skyler, J. S., Krischer, J. P., Bundy, B. N., Miller, J. L., Atkinson, M. A., Becker, D. J., Baidal, D. A., DiMeglio, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0494 · Cited by 183 · see citing works
Self-citation
CD4 T cell differentiation in type 1 diabetes
Walker, L. S. K., & von Herrath, M. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12672 · Cited by 182 · see citing works
Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease
Driver, J. P., SERREZE, D. V., & Chen, Y. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0204-1 · Cited by 179 · see citing works
Heterogeneity and endotypes in type 1 diabetes mellitus
REDONDO, M. J., & Morgan, N. G. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00853-0 · Cited by 172 · see citing works
Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis
TIGI study team, Leete, P., Oram, R. A., McDonald, T. J., Shields, B. M., Ziller, C., Hattersley, A. T., Richardson, S. J., & Morgan, N. G. (2020) · Diabetologia · doi:10.1007/s00125-020-05115-6 · Cited by 165 · see citing works
Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial
Forlenza, G. P., McVean, J., Beck, R. W., Bauza, C., Bailey, R., Buckingham, B., DiMeglio, L. A., Sherr, J. L., Clements, M., Neyman, A., et al. (2023) · JAMA · doi:10.1001/jama.2023.2064 · Cited by 169 · see citing works
Self-citation
Specific peripheral B cell tolerance defects in patients with multiple sclerosis
Kinnunen, T. T., Chamberlain, N., Morbach, H., Cantaert, T., Lynch, M. T., Preston‐Hurlburt, P., Herold, K. C., Hafler, D. A., O’Connor, K. C., & Meffre, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68775 · Cited by 165 · see citing works
The challenge of modulating β-cell autoimmunity in type 1 diabetes
Atkinson, M. A., Roep, B. O., Posgai, A. L., Wheeler, D. C. S., & Peakman, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30112-8 · Cited by 163 · see citing works
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J. L., Rosenthal, S. M., Adi, S., Jalaludin, M. Y., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2753-4 · Cited by 159 · see citing works
Self-citation
Genetics of diabetes – Are we missing the genes or the disease?
Groop, L., & Pociot, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.04.002 · Cited by 158 · see citing works
Immune mechanisms in type 1 diabetes
Wållberg, M., & Cooke, A. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.08.005 · Cited by 155 · see citing works
B cells in type 1 diabetes mellitus and diabetic kidney disease
Smith, M. J., Simmons, K. M., & Cambier, J. C. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.138 · Cited by 153 · see citing works
The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases
Meffre, E. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06347.x · Cited by 155 · see citing works
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose
Hao, W., Gitelman, S., DiMeglio, L. A., Boulware, D. C., Greenbaum, C. J., & for the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0360 · Cited by 149 · see citing works
Self-citation
Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes
Aronson, R., Gottlieb, P. A., Christiansen, J. S., Donner, T. W., Bosi, E., Bode, B. W., Pozzilli, P., & the DEFEND Investigator Group (2014) · Diabetes Care · doi:10.2337/dc13-0327 · Cited by 150 · see citing works
Self-citation
Effect of Cholecalciferol as Adjunctive Therapy With Insulin on Protective Immunologic Profile and Decline of Residual β-Cell Function in New-Onset Type 1 Diabetes Mellitus
Gabbay, M. A. L., Sato, M. N., Finazzo, C., Duarte, A. J. S., & Dib, S. A. (2012) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpediatrics.2012.164 · Cited by 149 · see citing works
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents
Besser, R. E. J., Bell, K. J., Couper, J., Ziegler, A., Wherrett, D. K., Knip, M., Speake, C., Casteels, K., Driscoll, K. A., Jacobsen, L. M., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13410 · Cited by 147 · see citing works
Self-citation
Current Concepts on the Pathogenesis of Type 1 Diabetes—Considerations for Attempts to Prevent and Reverse the Disease
Atkinson, M. A., von Herrath, M., Powers, A. C., & Clare-Salzler, M. J. (2015) · Diabetes Care · doi:10.2337/dc15-0144 · Cited by 145 · see citing works
Autoimmune Markers in Diabetes
Winter, W. E., & Schatz, D. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148205 · Cited by 142 · see citing works
Self-citation
IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients
Ferreira, R. C., Simons, H. Z., Thompson, W. S., Cutler, A. J., Dopico, X. C., Smyth, D. J., Mashar, M., Schuilenburg, H., Walker, N. M., Dunger, D. B., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3509-8 · Cited by 143 · see citing works
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial
Gitelman, S. E., Gottlieb, P. A., Rigby, M. R., Felner, E. I., Willi, S. M., Fisher, L. K., Moran, A., Gottschalk, M. E., Moore, W. V., Pinckney, A., et al. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70065-2 · Cited by 143 · see citing works
Self-citation
Current and future therapies for type 1 diabetes
von Scholten, B. J., Kreiner, F. F., Gough, S. C. L., & von Herrath, M. (2021) · Diabetologia · doi:10.1007/s00125-021-05398-3 · Cited by 148 · see citing works
β cell death and dysfunction during type 1 diabetes development in at-risk individuals.
Herold, K., Usmani-Brown, S., Ghazi, T., Lebastchi, J., Beam, C., Bellin, M., Ledizet, M., Sosenko, J. M., Krischer, J., & Palmer, J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78142 · Cited by 131 · see citing works
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
Todd, J. A., Evangelou, M., Cutler, A. J., Pękalski, M. Ł., Walker, N. M., Stevens, H. E., Porter, L., Smyth, D. J., Rainbow, D. B., Ferreira, R. C., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002139 · Cited by 138 · see citing works
PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes
Nasr, M. B., Tezza, S., D’Addio, F., Mameli, C., Usuelli, V., Maestroni, A., Corradi, D., Belletti, S., Albarello, L., Becchi, G., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7543 · Cited by 138 · see citing works
Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
Luo, X., Herold, K. C., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.002 · Cited by 136 · see citing works
NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets
Hu, C., Ding, H., Li, Y., Pearson, J. A., Zhang, X., Flavell, R. A., Wong, F. S., & Li, W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513509112 · Cited by 136 · see citing works
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Gitelman, S. E., Bundy, B. N., Ferrannini, E., Lim, N., Blanchfield, L., DiMeglio, L. A., Felner, E. I., Gaglia, J. L., Gottlieb, P. A., Long, S. A., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00139-x · Cited by 135 · see citing works
Self-citation
Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity
Bliddal, S., Nielsen, C. H., & Feldt‐Rasmussen, U. (2017) · F1000Research · doi:10.12688/f1000research.11535.1 · Cited by 133 · see citing works
Extracorporeal Photopheresis—An Overview
Cho, A., Jantschitsch, C., & Knobler, R. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00236 · Cited by 131 · see citing works
Anti-Islet Autoantibodies in Type 1 Diabetes
Kawasaki, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210012 · Cited by 139 · see citing works
Immune modulation in humans: implications for type 1 diabetes mellitus
Roep, B. O., & Tree, T. I. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.2 · Cited by 130 · see citing works
Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives
Pathak, V., Pathak, N., O'Neill, C., Guduric-Fuchs, J., & Medina, R. (2019) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551419844521 · Cited by 116 · see citing works
Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine
Roep, B. O., Wheeler, D. C. S., & Peakman, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30109-8 · Cited by 126 · see citing works
B-Cell Cross-Presentation of Autologous Antigen Precipitates Diabetes
Mariño, E., Tan, B. M., Binge, L. C., Mackay, C. R., & Grey, S. T. (2012) · Diabetes · doi:10.2337/db12-0006 · Cited by 125 · see citing works
Engineering immunomodulatory biomaterials for type 1 diabetes
Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0112-5 · Cited by 126 · see citing works
Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes
Frazzei, G., van Vollenhoven, R., de Jong, B. A., Siegelaar, S. E., & van Schaardenburg, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899372 · Cited by 125 · see citing works
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
the Immune Tolerance Network, Perdigoto, A. L., Preston‐Hurlburt, P., Clark, P. L., Long, S. A., Linsley, P. S., Harris, K. M., Gitelman, S., Greenbaum, C. J., Gottlieb, P. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4786-9 · Cited by 124 · see citing works
Self-citation
B cells and Autoimmunity
Pillai, S., Mattoo, H., & Cariappa, A. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.10.007 · Cited by 132 · see citing works
Homeostatic regulation of T cell trafficking by a B cell–derived peptide is impaired in autoimmune and chronic inflammatory disease
Chimen, M., McGettrick, H. M., Apta, B. H. R., Kuravi, S. J., Yates, C. M., Kennedy, A., Odedra, A., Alassiri, M., Harrison, M., Martin, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3842 · Cited by 119 · see citing works
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group
Matthews, J. B., Staeva, T. P., Bernstein, P., Peakman, M., & von Herrath, M. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04153.x · Cited by 115 · see citing works

original article Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H. J., Becker, D. J., Gitelman, S. E., Gol, R., Moran, A. M., Schatz, D. A., Lachin, J. M., Sc., D., et al. (2014)
Self-citation
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Pescovitz, M. D., Greenbaum, C. J., Bundy, B. N., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., Moran, A., Raskin, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0626 · Cited by 290 · see citing works
Self-citation
B-Lymphocyte Depletion With Rituximab and b-Cell Function: Two-Year Results OBJECTIVE
(2016)
Selective depletion of B lymphocytes with rituximab preserves β-cell function
Heath, V. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.279
Increased T Cell Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes
Herold, K. C., Pescovitz, M. D., McGee, P., Krause-Steinrauf, H. J., Spain, L. M., Bourcier, K., Asare, A. L., Liu, Z., Lachin, J. M., Dosch, H. M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100539 · Cited by 84 · see citing works
Self-citation

Authors: Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., & Skyler, J. S.
Affiliations: Indiana University School of Medicine (US)
Benaroya Research Institute (US)
George Washington University (US)
University of Pittsburgh (US)
University of California, San Francisco (US)
Columbia University (US)
University of Colorado Health (US)
University of Miami (US)
University of Minnesota (US)
The University of Texas Southwestern Medical Center (US)
University of Florida (US)
University of Toronto (CA)
Stanford University (US)
ORCID: Greenbaum, Carla J.
Krause-Steinrauf, Heidi
Gitelman, Stephen E.
Gottlieb, Peter A.
Marks, Jennifer B.
Moran, Antoinette M.
Rodriguez, Henry
Schatz, Desmond A.
Wherrett, Diane
Wilson, Darrell M.
Lachin, John M.
Skyler, Jay S.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-11-26
Volume: 361
Issue: 22
Pages: 2143-2152
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0904452
PMC: PMC6410357
OpenAlex: W2064431167
Cited by: 1,093
References: 39
Citations by year: 2026: 45 · 2025: 65 · 2024: 56 · 2023: 55 · 2022: 56 · 2021: 64 · 2020: 53 · 2019: 49 · 2018: 49 · 2017: 45 · 2016: 57 · 2015: 63 · 2014: 72 · 2013: 98 · 2012: 89
FWCI: 51.38
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Purdue University Indianapolis (Indiana University) (submittedVersion)
PMC
Funders: American Diabetes Association
Juvenile Diabetes Research Foundation International
Eli Lilly and Company
Biogen
Osiris Therapeutics
MacroGenics
National Institutes of Health
Genentech
National Institute of Allergy and Infectious Diseases
National Institute of Diabetes and Digestive and Kidney Diseases (R21DK077329, U01DK061058, U01DK061034, U01DK103282)
National Institute of Child Health and Human Development
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: rituximab, B-cell depletion, type 1 diabetes, beta-cell preservation, anti-CD20 monoclonal antibody, C-peptide, CD19+ B cells, immunopathogenesis, newly diagnosed type 1 diabetes, HbA1c, insulin dose
MeSH terms: Rituximab, Adolescent, Adult, Antibodies, Monoclonal, B-Lymphocytes, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Immunoglobulin M, Immunologic Factors, Male, Area Under Curve, Insulin-Secreting Cells, Young Adult, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks